Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
GRAIL reports news on its healthcare business focused on early cancer detection through the Galleri multi-cancer early detection blood test. The company uses next-generation sequencing, population-scale clinical studies, machine learning, software and automation within a targeted methylation-based platform designed to detect and identify multiple cancer types in earlier stages.
Recurring updates include Galleri revenue and test-volume trends, clinical data from programs such as NHS-Galleri and PATHFINDER 2, regulatory and evidence-generation activity, health-system access initiatives, commercial partnerships, conference presentations, equity incentive grants and governance changes. Company announcements also describe how its platform may support screening and precision oncology uses, including risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring and recurrence monitoring.
GRAIL (Nasdaq: GRAL) reported full PATHFINDER 2 results in 35,878 adults 50+ using the Galleri multi-cancer early detection blood test alongside standard screenings.
Adding Galleri increased screen-detected cancers up to 6.5-fold, with high specificity, 60.3% positive predictive value, strong episode sensitivity, and low invasive procedure rates.
GRAIL (Nasdaq: GRAL) reported full NHS-Galleri trial results at the 2026 ASCO Meeting. In 142,250 adults screened annually with the Galleri blood test plus standard screening versus standard screening alone, the primary endpoint—a reduction in combined Stage III/IV diagnoses in 12 cancers—was not met.
However, a pre-specified secondary endpoint showed Stage IV diagnoses for these cancers fell by 9%, 22% and 26% in the first, second and third rounds, for a 14% overall reduction. Stage I-II diagnoses rose 16%, screen-detected cancers increased four-fold, emergency-presenting cancers declined 25%, and no serious related adverse events were reported.
GRAIL (Nasdaq: GRAL) granted inducement equity awards in the form of restricted stock units (RSUs) covering an aggregate of 34,350 shares of common stock to 56 newly hired non-executive employees.
The RSUs, issued under GRAIL's Inducement Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4), vest over about four years, with 25% vesting on May 31, 2027 and annually thereafter, subject to continued employment.
GRAIL (Nasdaq: GRAL) announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9 at 11:20 a.m. ET.
Live and replay webcasts will be available in the investor relations section of GRAIL's website for at least 30 days.
GRAIL (Nasdaq: GRAL) announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 7:35 a.m. ET.
Live and replay webcasts will be available in the investor relations section of GRAIL's website for at least 30 days.
GRAIL (Nasdaq: GRAL) reported Q1 2026 results on May 5, 2026. Total revenue rose 28% year-over-year to $40.8 million and Galleri revenue grew 37% to $39.8 million. Galleri test volume increased 50% to more than 56,000 tests. Net loss was $93.2 million; cash and short-term investments were $823.1 million. The FDA accepted the PMA for review and Epic EHR integration is planned for broad availability by end of 2026. New NHS-Galleri and PATHFINDER 2 data will be presented at ASCO 2026.
GRAIL (Nasdaq: GRAL) will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 8:40 a.m. PT. Live and replay webcasts will be available via the investor relations site and archived for at least 30 days.
GRAIL (Nasdaq: GRAL) will issue first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.
A live webcast and recorded replay will be available at the investor relations site, and registration is requested for the teleconference and webcast to ensure timely connection.
GRAIL (Nasdaq: GRAL) will present late-breaking NHS-Galleri and PATHFINDER 2 results at the 2026 ASCO Annual Meeting, May 29–June 2 in Chicago.
The NHS-Galleri randomized trial screened >142,000 participants; PATHFINDER 2 includes >32,000 evaluable participants, >174,000 combined, with oral presentations on May 30–31, 2026.
GRAIL (Nasdaq: GRAL) announced on April 7, 2026 a collaboration with Epic to integrate the Galleri multi-cancer early detection test into the Epic EHR via Epic Aura. The integration aims to enable ordering, results delivery, and follow-up within existing clinician workflows for approximately 450 health systems, with implementation planning begun in Q1 2026 and broad availability expected by the end of 2026.